| Literature DB >> 31333155 |
Samuel C Ficenec1, John S Schieffelin1, Susan D Emmett2,3,4.
Abstract
The neglected tropical diseases Zika, Ebola, and Lassa fever (LF) have all been noted to cause some degree of hearing loss (HL). Hearing loss is a chronic disability that can lead to a variety of detrimental effects, including speech and language delays in children, decreased economic productivity in adults, and accelerated cognitive decline in older adults. The objective of this review is to summarize what is known regarding HL secondary to these viruses. Literature for this review was gathered using the PubMed database. Articles were excluded if there were no data of the respective viruses, postinfectious complications, or conditions related to survivorship. A total of 50 articles were included in this review. Fourteen articles discussing Zika virus and subsequent complications were included. Across these studies, 56 (21.2%) of 264 Zika-infected individuals were found to have HL. Twenty-one articles discussing Ebola virus and subsequent complications were included, with 190 (5.7%) of 3,350 Ebola survivors found to have HL. Fifteen additional articles discussing LF and subsequent complications were included. Of 926 individuals with LF, 79 (8.5%) were found to have HL. These results demonstrate a relationship between HL and infection. The true prevalence is likely underestimated, however, because of lack of standardization of reporting and measurement. Future studies of viral sequelae would benefit from including audiometric evaluation. This information is critical to understanding pathophysiology, preventing future cases of this disability, and improving quality of life after survival of infection.Entities:
Mesh:
Year: 2019 PMID: 31333155 PMCID: PMC6726950 DOI: 10.4269/ajtmh.18-0934
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 2.345
Figure 1.Literature search results.
Adult and congenital Zika hearing loss (HL) findings by year
| First author | Publication year | Study type | Sample size ( | Age group | HL Screening Method | HL result ( | Unilateral HL ( | Bilateral HL ( | Control group ( |
|---|---|---|---|---|---|---|---|---|---|
| Tappe[ | 2014 | Case report | 1 | Adult | Self-report | 1 (100) | NR | NR | ND |
| M.E.R.G[ | 2015 | Cross-sectional | 23* | Neonatal | OAE | 2 (9) | NR | NR | ND |
| Leal[ | 2016 | Retrospective cohort | 70 | Pediatric | ABR to click and tone burst stimuli | 5 (6) | NR | NR | ND |
| Leal[ | 2016 | Case series | 2 | Neonatal | Transient OAE followed by ABR to click stimuli | 1 (50) | NR | NR | ND |
| Vinhaes[ | 2017 | Case series | 3 | Adult | Audiometry | 3 (100) | 1 | 2 | ND |
| Martins[ | 2017 | Case series | 2 | Adult | Audiometry | 1 (50) | 1 | 0 | ND |
| Satterfeldt[ | 2017 | Cross-sectional | 19 | Pediatric | Physician-reported HINE assessment | 13 (68) | NR | NR | ND |
| Santos[ | 2017 | Case series | 2 | Neonatal | Evoked OAE followed by ABR | 1 (50) | NR | NR | ND |
| Wheeler[ | 2018 | Cross-sectional | 47 | Pediatric | No response to voice or sound | 13 (28) | NR | NR | ND |
| Does not look for sound | 8 (17) | ||||||||
| No response to word “No” | 20 (43) | ||||||||
| de Laval[ | 2018 | Prospective cohort | 49 | Adult | NR | NR | NR | NR | ND |
| Ventura[ | 2018 | Case report | 1 | Neonatal | ABR to click stimuli | 1 (100) | 1 | 0 | ND |
| Franca[ | 2018 | Cross-sectional | 8 | Pediatric | NR | NR | NR | NR | ND |
| Vianna[ | 2019 | Prospective cohort | 26 | Pediatric | ABR | 2 (8) | NR | NR | 65 (3) |
| Calle-Giraldo34 | 2019 | Prospective cohort | 68 | Neonatal | ABR | 6 (9) | 3 | 3 | ND |
ABR = auditory brainstem response; ND = not done; NR = not reported; OAE = otoacoustic emission; HINE = Hammersmith infant neurological examination Adult, 18 years or greater; pediatric, 0–24 months; neonatal, anomalies detected at birth.
* Total sample size of 104, only 23 screened for HL.
Ebola hearing loss (HL) findings by hearing screening method by year
| First author | Publication year | Study type | Sample size ( | Median age (years) | HL screening method | HL results ( | Days to HL onset (median DPI) | Control group ( |
|---|---|---|---|---|---|---|---|---|
| Rowe[ | 1999 | Prospective cohort | 29 | 27 | Audiometry | 18 (64.3) | < 180 | 152 (NR) |
| Bwaka[ | 1999 | Retrospective cohort | 103 | 38 | Self-Reported | 13 (12.6) | NR | ND |
| Clark[ | 2015 | Retrospective cohort | 70 | 40 | Questionnaire | 13 (27) | NR | 223 (10) |
| Qureshi[ | 2015 | Cross-sectional | 105 | 38.9* | Questionnaire | 0 (0) | NR | ND |
| Mattia[ | 2016 | Cross-sectional | 277 | 29 | Self-report | 17 (6) | 14 | ND |
| Jacobs[ | 2016 | Case report | 1 | 39 | Self-report | 1 (100) | 11 | ND |
| Tiffany[ | 2016 | Prospective cohort | 166 | 24.7† | Self-reported | 5 (3) | 31–60 | ND |
| Nanyonga[ | 2016 | Cross-sectional | 81 | 29 | Questionnaire | NR | NR | ND |
| Fallah[ | 2016 | Retrospective cohort | 70 | NR | NR | NR | NR | ND |
| Etard[ | 2017 | Cross-sectional | 802 | 28.4 | Self-reported | 19 (2.4) | 350 | ND |
| Shantha | 2017 | Cross-sectional | 96 | 38.6 | Self-reported | 10 (10.4) | NR | ND |
| Hereth-Hebert[ | 2017 | Prospective cohort | 341 | 26 | NR | NR | NR | ND |
| Wilson[ | 2018 | Cross-sectional | 242 | 30 | Questionnaire | 4 (1.6) | NR | ND |
| Jagadesh[ | 2018 | Retrospective case control | 27 | NR | Questionnaire | 5 (18.5) | NR | 54 |
| Kelly[ | 2018 | Cross-sectional | 20 | 53.2* | NR | NR | NR | 187 (NR) |
| Wing[ | 2018 | Retrospective cohort | 137 | 25 | Self-report | 30 (22) | NR | ND |
| Overholt[ | 2018 | Prospective cohort | 299 | 31 | NR | NR | NR | ND |
| Howlett[ | 2018 | Case series | 35 | 28 | Self-report | 3 (8.6%) | NR | ND |
| de St. Maurice[ | 2018 | Cross-sectional | 329 | 33† | Questionnaire | 19 (6) | NR | ND |
| Kelly[ | 2019 | Prospective cohort | 859 | 12–50+† | NR | NR | NR | ND |
| PREVAIL[ | 2019 | Prospective cohort | 966 | NR | Self-report | 66 (6.8%) | NR | 2,350 (2.2) |
DPI = days postinfection; ND = not done; NR = not reported.
* Age reported as mean age of sample.
† Only range of ages reported.
Lassa Fever HL Findings by year
| First author | Publication year | Study type | Sample size | Mean age (years) | HL screening method | HL results ( | Average severity of HL* | Unilateral HL | Bilateral HL | Days to HL onset (median DPI) | Control group ( |
|---|---|---|---|---|---|---|---|---|---|---|---|
| White[ | 1972 | Case series | 23 | 26.6 | Self-report | 4 (17.4) | NR | NR | NR | NR | ND |
| Mertens[ | 1973 | Cross-sectional | 10 | 20–56‡ | Self-report | 3 (30%) | NR | NR | NR | NR | ND |
| Grundy[ | 1980 | Case report | 1 | 25 | Self-report | 1 (100) | NR | 1 | 0 | 14 | ND |
| McCormick[ | 1987 | Case–control | 430 | NR | NR | 12 (2.8) | NR | 3 | 9 | 10–15 | ND |
| Frame[ | 1987 | Cross-sectional | 33 | < 1† | NR | NR | NR | NR | NR | NR | ND |
| Hirabayashi[ | 1988 | Case report | 1 | 48 | NR | NR | NR | NR | NR | NR | ND |
| Frame[ | 1989 | Retrospective | 246 | NR | NR | NR | NR | NR | NR | NR | ND |
| Cummins[ | 1990 | Prospective cohort | 49 | 30.2 | Audiometry | 14 (28.6) | Severe | 7 | 14 | 5-12 | ND |
| Cummins[ | 1990 | Case–control | 51 | 30.3 | Audiometry | 9 (17.6) | Moderate | 3 | 6 | NR | 45 (4) |
| Günther[ | 2001 | Case report | 1 | 56 | NR | NR | NR | NR | NR | NR | ND |
| Macher[ | 2006 | Case series | 2 | 34.5 | Audiometry | 1 (50) | NR | 1 | 0 | NR | ND |
| Okokhere[ | 2009 | Case series | 2 | 31 | Audiometry | 2 (100) | Severe | 0 | 2 | 9 | ND |
| Ibekwe[ | 2011 | Prospective cohort | 37 | 35.3 | Audiometry | 5 (13.5) | Severe | 0 | 5 | NR | 37 (0) |
| Grahn[ | 2016 | Case report | 1 | 72 | Self-report | 1 (100) | NR | 0 | 1 | 22 | ND |
| Choi[ | 2018 | Case report | 1 | 46 | Self-report | 1 (100) | NR | 0 | 1 | 5 | ND |
| Okokhere[ | 2018 | Retrospective cohort | 291 | 35 | NR | 0 (0) | NR | NR | NR | NR | ND |
DPI = days postinfection; HL = hearing loss; ND = not done; NR = not reported.
* Severity determined based on WHO standards.
† Ordinal data presented were used to calculate median age.
‡ Only range of ages reported.